Sophie Rebecca Thomas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sophie Rebecca Thomas has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Angela Casini
Chair of Medicinal and Bioinorganic Chemistry, School of Natural Sciences, Department of Chemistry, Technical University of Munich, Lichtenbergstr. 4, D-85748 Garching b. München, Germany
31 shared publications - Riccardo Bonsignore
Dipartimento di Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche, Università degli Studi di Palermo, Palermo 90128, Italy
5 shared publications - Giampaolo Barone
Dipartimento di Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche, Università degli Studi di Palermo, Palermo 90128, Italy
4 shared publications - Jia Min Chin
Institute of Functional Materials and Catalysis Faculty of Chemistry University of Vienna Vienna Austria
4 shared publications - Michael R. Reithofer
Institute of Inorganic Chemistry Faculty of Chemistry University of Vienna Vienna Austria
4 shared publications - Mihyun Park
Technical University of Munich
4 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 18 (38) , 20863-20872
One-pot installation of N-heterocyclic carbenes on gold nanoparticles through counterion-dependent mild-base activation
In this work, gold nanoparticles functionalized with N-heterocyclic carbenes are formed by a mild, one-pot activation with multiple NHC precursors. Mechanistic work rules out the formation of previously observed HCO 3 − or CO 2 adducts.
- 8 October 2026
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 18 (38) , 20863-20872
Open AccessOne-pot installation of N-heterocyclic carbenes on gold nanoparticles through counterion-dependent mild-base activation
In this work, gold nanoparticles functionalized with N-heterocyclic carbenes are formed by a mild, one-pot activation with multiple NHC precursors. Mechanistic work rules out the formation of previously observed HCO 3 − or CO 2 adducts.
- Open Access
- 5 January 2026
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 21 (1) , 170-186
A Gold-PROTAC Degrades the Oncogenic Tyrosine Kinase MERTK: Insights into the Degradome from a Steady-State System
Proteolysis targeting chimeras (PROTACs) are bifunctional molecules designed to induce the degradation of specific proteins within a cell. While most PROTACs are noncovalent interactors, covalent PROTACs may benefit from improved selectivity and pharmacodynamics, yet remain largely understudied. Here, a covalent gold-based PROTAC (AuPROTAC) was synthesized, featuring a Au(III)-warhead, known to induce cysteine-arylation in a gold-templated two-step mechanism, linked to a cereblon binding moiety. The degradome of the AuPROTAC was characterized by establishing a cycloheximide chase assay in a nonproliferative steady-state HL-60 cell culture, enabling the identification of PROTAC degradation targets uncoupled from confounding effects originating from cell-cycle-dependent translational patterns. The method was verified using the known SMARCA2 and PBRM1-degrader ACBI2. AuPROTAC could degrade the oncogenic tyrosine kinase MERTK and the thioredoxin-like 1 protein TXNL1. Their degradation was successfully rescued by proteasome inhibition. Proteome-wide degradation selectivity was further characterized by ranking the degraded targets according to the reduction extent of their protein half-lives. Interestingly, the AuPROTAC degraded a relatively limited number of proteins (95) when compared to ACBI2 (221).
- 5 January 2026
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 21 (1) , 170-186
Open AccessA Gold-PROTAC Degrades the Oncogenic Tyrosine Kinase MERTK: Insights into the Degradome from a Steady-State System
Proteolysis targeting chimeras (PROTACs) are bifunctional molecules designed to induce the degradation of specific proteins within a cell. While most PROTACs are noncovalent interactors, covalent PROTACs may benefit from improved selectivity and pharmacodynamics, yet remain largely understudied. Here, a covalent gold-based PROTAC (AuPROTAC) was synthesized, featuring a Au(III)-warhead, known to induce cysteine-arylation in a gold-templated two-step mechanism, linked to a cereblon binding moiety. The degradome of the AuPROTAC was characterized by establishing a cycloheximide chase assay in a nonproliferative steady-state HL-60 cell culture, enabling the identification of PROTAC degradation targets uncoupled from confounding effects originating from cell-cycle-dependent translational patterns. The method was verified using the known SMARCA2 and PBRM1-degrader ACBI2. AuPROTAC could degrade the oncogenic tyrosine kinase MERTK and the thioredoxin-like 1 protein TXNL1. Their degradation was successfully rescued by proteasome inhibition. Proteome-wide degradation selectivity was further characterized by ranking the degraded targets according to the reduction extent of their protein half-lives. Interestingly, the AuPROTAC degraded a relatively limited number of proteins (95) when compared to ACBI2 (221).
- Open Access
- 12 November 2025
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 17 (47) , 27599-27608
Water-soluble N-heterocyclic carbene stabilized gold nanoparticles by top-down synthesis: performance in catalysis and photoacoustic imaging
N-heterocyclic carbene (NHC) stabilized gold nanoparticles synthesized by the 'top-down' approach show greater promise in catalysis and photoacoustic imaging compared to their 'bottom-up' counterparts.
- 12 November 2025
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 17 (47) , 27599-27608
Open AccessWater-soluble N-heterocyclic carbene stabilized gold nanoparticles by top-down synthesis: performance in catalysis and photoacoustic imaging
N-heterocyclic carbene (NHC) stabilized gold nanoparticles synthesized by the 'top-down' approach show greater promise in catalysis and photoacoustic imaging compared to their 'bottom-up' counterparts.
- Open Access
- 12 September 2025
- Published by American Chemical Society (ACS) in Inorganic Chemistry
- Vol. 64 (38) , 19316-19324
Bidentate Acyclic Diamino Carbene-Stabilized Gold Nanoparticles from Symmetric and Asymmetric Gold(I) Complexes: Synthesis, Characterization, and Catalytic Activity
A series of gold nanoparticles (AuNPs) stabilized by bidentate acyclic diamino carbenes (ADCs) were synthesized via the reduction of dimeric gold(I) complexes. The resulting ADC-AuNPs were characterized by NMR spectroscopy, UV-vis spectroscopy, X-ray photoelectron spectroscopy (XPS), transmission electron microscopy (TEM), and thermogravimetric analysis (TGA), revealing nanoparticles with a narrow size distribution and sizes ranging from 1.7 to 3.3 nm. This synthetic approach was extended to an asymmetric dinuclear ADC-gold(I) complex, affording slightly larger AuNPs (∼4 nm) upon reduction. The ADC-AuNPs with shorter linkers exhibited significant catalytic activity for the reduction of 4-nitrophenol, demonstrating a versatile and efficient route to catalytically active gold nanoparticles stabilized by both symmetric and asymmetric ADC ligands.
- 12 September 2025
- Published by American Chemical Society (ACS) in Inorganic Chemistry
- Vol. 64 (38) , 19316-19324
Open AccessBidentate Acyclic Diamino Carbene-Stabilized Gold Nanoparticles from Symmetric and Asymmetric Gold(I) Complexes: Synthesis, Characterization, and Catalytic Activity
A series of gold nanoparticles (AuNPs) stabilized by bidentate acyclic diamino carbenes (ADCs) were synthesized via the reduction of dimeric gold(I) complexes. The resulting ADC-AuNPs were characterized by NMR spectroscopy, UV-vis spectroscopy, X-ray photoelectron spectroscopy (XPS), transmission electron microscopy (TEM), and thermogravimetric analysis (TGA), revealing nanoparticles with a narrow size distribution and sizes ranging from 1.7 to 3.3 nm. This synthetic approach was extended to an asymmetric dinuclear ADC-gold(I) complex, affording slightly larger AuNPs (∼4 nm) upon reduction. The ADC-AuNPs with shorter linkers exhibited significant catalytic activity for the reduction of 4-nitrophenol, demonstrating a versatile and efficient route to catalytically active gold nanoparticles stabilized by both symmetric and asymmetric ADC ligands.
- Open Access
- 13 August 2025
- Published by American Chemical Society (ACS) in ChemRxiv
A Gold-PROTAC degrades the oncogenic tyrosine kinase MERKT: insights into the degradome from a steady-state system
Targeted protein degradation is a valuable strategy to eliminate disease-relevant proteins. Among other classes, proteolysis targeting chimeras (PROTACs) are bifunctional molecules that induce the proximity of a recruiter E3 ligase and the target protein of interest for ubiquitination and subsequent degradation by the proteasome. While most PROTACs are non-covalent interactors, covalent PROTACs may benefit from increased selectivity and improved pharmacodynamics, yet remain largely understudied. In this context, a gold-based PROTAC (AuPROTAC) was synthesized, consisting of a cyclometalated Au(III) warhead, known to induce covalent cysteine-arylation in a gold-templated two-step mechanism, linked to a cereblon binding moiety. The degradome of the covalent AuPROTAC was characterized by establishing a cycloheximide chase assay, which was performed in a non-proliferative steady-state HL-60 cell culture system that maintained a static protein turnover and efficiently decoupled protein degradation from down-regulation. The method was verified with the known SMARCA2 and PBRM1-degrader ACBI2. Interestingly, amongst the possible targets, AuPROTAC could degrade the oncogenic tyrosine kinase MERTK and the thioredoxin-like 1 protein TXNL1, while their degradation was successfully rescued by proteasome inhibition. The investigated PROTACs were found to affect protein half-lives; therefore, proteome-wide degradation selectivity was further characterized by ranking degraded targets based on the acceleration of protein half-lives. Interestingly, the AuPROTAC degraded a relatively limited number of proteins (95) when compared to the targeted ACBI2 (221). Overall, the established approach can be used to efficiently explore degradomes of CRBN and VHL recruiter-based PROTACs.
- 13 August 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessA Gold-PROTAC degrades the oncogenic tyrosine kinase MERKT: insights into the degradome from a steady-state system
Targeted protein degradation is a valuable strategy to eliminate disease-relevant proteins. Among other classes, proteolysis targeting chimeras (PROTACs) are bifunctional molecules that induce the proximity of a recruiter E3 ligase and the target protein of interest for ubiquitination and subsequent degradation by the proteasome. While most PROTACs are non-covalent interactors, covalent PROTACs may benefit from increased selectivity and improved pharmacodynamics, yet remain largely understudied. In this context, a gold-based PROTAC (AuPROTAC) was synthesized, consisting of a cyclometalated Au(III) warhead, known to induce covalent cysteine-arylation in a gold-templated two-step mechanism, linked to a cereblon binding moiety. The degradome of the covalent AuPROTAC was characterized by establishing a cycloheximide chase assay, which was performed in a non-proliferative steady-state HL-60 cell culture system that maintained a static protein turnover and efficiently decoupled protein degradation from down-regulation. The method was verified with the known SMARCA2 and PBRM1-degrader ACBI2. Interestingly, amongst the possible targets, AuPROTAC could degrade the oncogenic tyrosine kinase MERTK and the thioredoxin-like 1 protein TXNL1, while their degradation was successfully rescued by proteasome inhibition. The investigated PROTACs were found to affect protein half-lives; therefore, proteome-wide degradation selectivity was further characterized by ranking degraded targets based on the acceleration of protein half-lives. Interestingly, the AuPROTAC degraded a relatively limited number of proteins (95) when compared to the targeted ACBI2 (221). Overall, the established approach can be used to efficiently explore degradomes of CRBN and VHL recruiter-based PROTACs.
- Open Access
- 13 August 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (16) , 17516-17526
N-Heterocyclic Carbenes as Ligands to 198Au(I)-Radiolabeled Compounds: A New Platform for Radiopharmaceutical Design
The radionuclide 198Au, with a half-life of 2.7 days, emits γ radiation ideal for diagnostic purposes and generates β– particles suitable for effective cancer radiotherapy, making it a perfect nuclide for “theranostics”. However, the application of coordination compounds of Au(I)/Au(III) in medicine is limited by their instability in vivo. Here, we explore N-heterocyclic carbene (NHC) organometallic chemistry to stabilize 198Au(I) in radiopharmaceuticals. Thus, Au(I) NHC compounds featuring different scaffolds were selected for 198Au radiolabeling. Eventually, two compounds featuring imidazole (AuNHC-1) and theophylline (AuTMX2) scaffolds were successfully radiolabeled (radiochemical purity = 92.9% and 40.2%, respectively). Instead, two peptidic Au(I) benzimidazolylidene derivatives, capable of blood–brain barrier translocation in vitro, were subjected to ligand exchange reactions under the applied radiolabeling conditions. The obtained proof-of-concept results showed that NHCs are suitable ligands to achieve isotope exchange in Au(I) complexes. Overall, our work reveals the still untapped potential of organometallic chemistry in radiopharmaceutical design.
- 13 August 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (16) , 17516-17526
Open AccessN-Heterocyclic Carbenes as Ligands to 198Au(I)-Radiolabeled Compounds: A New Platform for Radiopharmaceutical Design
The radionuclide 198Au, with a half-life of 2.7 days, emits γ radiation ideal for diagnostic purposes and generates β– particles suitable for effective cancer radiotherapy, making it a perfect nuclide for “theranostics”. However, the application of coordination compounds of Au(I)/Au(III) in medicine is limited by their instability in vivo. Here, we explore N-heterocyclic carbene (NHC) organometallic chemistry to stabilize 198Au(I) in radiopharmaceuticals. Thus, Au(I) NHC compounds featuring different scaffolds were selected for 198Au radiolabeling. Eventually, two compounds featuring imidazole (AuNHC-1) and theophylline (AuTMX2) scaffolds were successfully radiolabeled (radiochemical purity = 92.9% and 40.2%, respectively). Instead, two peptidic Au(I) benzimidazolylidene derivatives, capable of blood–brain barrier translocation in vitro, were subjected to ligand exchange reactions under the applied radiolabeling conditions. The obtained proof-of-concept results showed that NHCs are suitable ligands to achieve isotope exchange in Au(I) complexes. Overall, our work reveals the still untapped potential of organometallic chemistry in radiopharmaceutical design.
- Top Cited PapersOpen Access
- 22 July 2025
- Published by Royal Society of Chemistry (RSC) in Inorganic Chemistry Frontiers
- Vol. 12 (21) , 6435-6459
Rational design of metal–organic frameworks (MOFs) as hosts for nanoparticles in catalytic applications: concepts, strategies, and emerging trends
Metal–organic frameworks (MOFs) are a versatile class of porous coordination materials that have found widespread application in various fields, particularly as heterogeneous catalysts.
- 22 July 2025
- Published by Royal Society of Chemistry (RSC) in Inorganic Chemistry Frontiers
- Vol. 12 (21) , 6435-6459
Top Cited PapersOpen AccessRational design of metal–organic frameworks (MOFs) as hosts for nanoparticles in catalytic applications: concepts, strategies, and emerging trends
Metal–organic frameworks (MOFs) are a versatile class of porous coordination materials that have found widespread application in various fields, particularly as heterogeneous catalysts.
- Open Access
- 4 June 2025
- Published by Wiley in ChemBioChem
- Vol. 26 (14) , e202500347
Harnessing Organometallic Au(III) Complexes as Precision Scaffolds for Next‐Generation Therapeutic and Imaging Agents
Au(III) organometallic complexes, particularly cyclometalated Au(III) compounds, have emerged as powerful tools in catalysis and bioinorganic chemistry, offering unique reactivity distinct from their Au(I) counterparts. Among their most interesting transformations, C–S cross‐coupling reactions have become a selective strategy for cysteine arylation, enabling site‐specific modifications of peptides and proteins. This review provides a comprehensive overview of cyclometalated Au(III) complexes in C–S bond formation, detailing the mechanistic insights, ligand effects, and electronic factors that dictate their reactivity. The role of ancillary ligands in tuning stability and selectivity is critically assessed, alongside advancements in structural modifications that enhance catalytic efficiency. Beyond fundamental C–S cross‐coupling, the broader applications of these Au(III) complexes are explored, including enzyme inhibition, metabolic disruption, and transmembrane protein modulation, with implications in anticancer therapy, antimicrobial strategies, and in vivo catalytic transformations. By bridging fundamental organometallic reactivity with innovative biomedical applications, this review highlights the potential of cyclometalated Au(III) complexes as next‐generation catalysts for both synthetic and therapeutic innovations.
- 4 June 2025
- Published by Wiley in ChemBioChem
- Vol. 26 (14) , e202500347
Open AccessHarnessing Organometallic Au(III) Complexes as Precision Scaffolds for Next‐Generation Therapeutic and Imaging Agents
Au(III) organometallic complexes, particularly cyclometalated Au(III) compounds, have emerged as powerful tools in catalysis and bioinorganic chemistry, offering unique reactivity distinct from their Au(I) counterparts. Among their most interesting transformations, C–S cross‐coupling reactions have become a selective strategy for cysteine arylation, enabling site‐specific modifications of peptides and proteins. This review provides a comprehensive overview of cyclometalated Au(III) complexes in C–S bond formation, detailing the mechanistic insights, ligand effects, and electronic factors that dictate their reactivity. The role of ancillary ligands in tuning stability and selectivity is critically assessed, alongside advancements in structural modifications that enhance catalytic efficiency. Beyond fundamental C–S cross‐coupling, the broader applications of these Au(III) complexes are explored, including enzyme inhibition, metabolic disruption, and transmembrane protein modulation, with implications in anticancer therapy, antimicrobial strategies, and in vivo catalytic transformations. By bridging fundamental organometallic reactivity with innovative biomedical applications, this review highlights the potential of cyclometalated Au(III) complexes as next‐generation catalysts for both synthetic and therapeutic innovations.
- Open Access
- 23 May 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Bidentate Acyclic Diamino Carbene-Stabilized Gold Nanoparticles from Symmetric and Asymmetric Gold(I) Complexes: Synthesis, Characterization, and Catalytic Activity
A series of gold nanoparticles (AuNPs) stabilized by bidentate acyclic diamino carbenes (ADCs) were synthesized via the reduction of dimeric gold(I) complexes. The resulting ADC-AuNPs were characterized by NMR spectroscopy, UV-Vis spectroscopy, transmission electron microscopy (TEM), and thermogravimetric analysis (TGA), revealing monodisperse particles with sizes ranging from 1.7 to 3.3 nm. This synthetic approach was extended to an asymmetric dinuclear ADC-gold(I) complex, affording slightly larger AuNPs (~4 nm) upon reduction. The ADC-AuNPs with shorter linkers exhibited significant catalytic activity for the reduction of 4-nitrophenol, demonstrating a versatile and efficient route to catalytically active gold nanoparticles stabilized by both symmetric and asymmetric ADC ligands.
- 23 May 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessBidentate Acyclic Diamino Carbene-Stabilized Gold Nanoparticles from Symmetric and Asymmetric Gold(I) Complexes: Synthesis, Characterization, and Catalytic Activity
A series of gold nanoparticles (AuNPs) stabilized by bidentate acyclic diamino carbenes (ADCs) were synthesized via the reduction of dimeric gold(I) complexes. The resulting ADC-AuNPs were characterized by NMR spectroscopy, UV-Vis spectroscopy, transmission electron microscopy (TEM), and thermogravimetric analysis (TGA), revealing monodisperse particles with sizes ranging from 1.7 to 3.3 nm. This synthetic approach was extended to an asymmetric dinuclear ADC-gold(I) complex, affording slightly larger AuNPs (~4 nm) upon reduction. The ADC-AuNPs with shorter linkers exhibited significant catalytic activity for the reduction of 4-nitrophenol, demonstrating a versatile and efficient route to catalytically active gold nanoparticles stabilized by both symmetric and asymmetric ADC ligands.
- Open Access
- 17 April 2025
- Published by American Chemical Society (ACS) in ChemRxiv
N-Heterocyclic Carbenes as Ligands to 198Au(I) Radiolabeled Compounds: a New Platform for Radiopharmaceutical Design
The application of Au(I) ions in pharmaceuticals, including in nuclear medicine, is limited by their instability towards reduction in vivo. The gold radionuclide 198Au with a half-life of 2.7 days emits gamma radiation ideal for diagnostic purposes and also generates β- particles suitable for effective cancer radiotherapy, making it a perfect nuclide for ‘theranostics’. Here, we explore N-heterocyclic carbene (NHC) organometallic chemistry to stabilize 198Au(I) in radiopharmaceuticals. Thus, different Au(I) NHC compounds featuring different scaffolds have been selected for 198Au radiolabeling. Two new benzimidazol-2-ylidene Au(I) complexes bearing peptide ligands enabling blood brain barrier translocation in vitro have also been synthesized and their radiolabeling attempted. The obtained proof-of-concept results showed that NHCs are suitable ligands to achieve isotope exchange in Au(I) complexes, with imidazole derivatives being particularly stable, also in the presence of AuCl(THT) and human serum albumin. Overall, our work reveals the still untapped potential of organometallic chemistry in radiopharmaceutical design.
- 17 April 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessN-Heterocyclic Carbenes as Ligands to 198Au(I) Radiolabeled Compounds: a New Platform for Radiopharmaceutical Design
The application of Au(I) ions in pharmaceuticals, including in nuclear medicine, is limited by their instability towards reduction in vivo. The gold radionuclide 198Au with a half-life of 2.7 days emits gamma radiation ideal for diagnostic purposes and also generates β- particles suitable for effective cancer radiotherapy, making it a perfect nuclide for ‘theranostics’. Here, we explore N-heterocyclic carbene (NHC) organometallic chemistry to stabilize 198Au(I) in radiopharmaceuticals. Thus, different Au(I) NHC compounds featuring different scaffolds have been selected for 198Au radiolabeling. Two new benzimidazol-2-ylidene Au(I) complexes bearing peptide ligands enabling blood brain barrier translocation in vitro have also been synthesized and their radiolabeling attempted. The obtained proof-of-concept results showed that NHCs are suitable ligands to achieve isotope exchange in Au(I) complexes, with imidazole derivatives being particularly stable, also in the presence of AuCl(THT) and human serum albumin. Overall, our work reveals the still untapped potential of organometallic chemistry in radiopharmaceutical design.